ODYY · Odyssey Health, Inc.
$0.01
0.00 (-2.02%)
At close · Sep 1
Going-concern doubt
— flagged Jun 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The operating deficit and negative working capital at April 30, 2026, indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Jun 12, 2026
Market Cap
$1.01M
Shares
100.97M
ODYY metrics
46 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.01
Market cap
$1.01M
Price action
19 metricsPrice change (1W)
-3.0%
Price change (30D)
-1.0%
Price change (3M)
-30.7%
Price change (6M)
-83.3%
Price change (YTD)
-70.6%
Price change (1Y)
-88.7%
Trailing year
Price change (5Y)
-97.6%
52-week high
$0.11
52-week low
$0.00
Change from 52-week high
-90.8%
Change from 52-week low
+142.5%
Annualized volatility
263.0%
Beta
2.6
RSI (14D)
53.2
Price vs SMA 50
+19.0%
Price vs SMA 200
-78.3%
Avg volume (3M)
231,934
Relative volume
0.8
Average dollar volume
$1,996
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
100.97M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-353.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$938,364
Net income (TTM)
−$3.57M
Trailing 12 months
Diluted EPS (TTM)
$-0.03
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-955.4%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.13M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-0.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$297,806
Total assets
$373,779
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$934,977
Capital expenditures (TTM)
—
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
$0
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged